Authors | Jeffrey L Wolf, David Siegel, Hartmut Goldschmidt, Katharine Hazell, Priscille M Bourquelot, Bourras R Bengoudifa, Jeffrey Matous, Ravi Vij, Margarida de Magalhaes-Silverman, Rafat Abonour, Kenneth C Anderson, Sagar Lonial |
Journal | Leukemia & lymphoma
(Leuk Lymphoma)
Vol. 53
Issue 9
Pg. 1820-3
(Sep 2012)
ISSN: 1029-2403 [Electronic] United States |
PMID | 22288662
(Publication Type: Clinical Trial, Phase II, Letter, Multicenter Study)
|
Chemical References |
- Antineoplastic Agents
- Boronic Acids
- Histone Deacetylase Inhibitors
- Hydroxamic Acids
- Indoles
- Pyrazines
- Thalidomide
- Bortezomib
- Panobinostat
- Lenalidomide
|
Topics |
- Adult
- Aged
- Antineoplastic Agents
(therapeutic use)
- Area Under Curve
- Boronic Acids
(therapeutic use)
- Bortezomib
- Diarrhea
(chemically induced)
- Drug Administration Schedule
- Drug Resistance, Neoplasm
- Female
- Histone Deacetylase Inhibitors
(adverse effects, pharmacokinetics, therapeutic use)
- Humans
- Hydroxamic Acids
(adverse effects, pharmacokinetics, therapeutic use)
- Indoles
(adverse effects, pharmacokinetics, therapeutic use)
- Lenalidomide
- Male
- Metabolic Clearance Rate
- Middle Aged
- Multiple Myeloma
(drug therapy, metabolism, pathology)
- Nausea
(chemically induced)
- Neutropenia
(chemically induced)
- Panobinostat
- Pyrazines
(therapeutic use)
- Recurrence
- Remission Induction
- Thalidomide
(analogs & derivatives, therapeutic use)
- Thrombocytopenia
(chemically induced)
- Treatment Outcome
|